CN110167546A - 同位素修饰的组分及其治疗用途 - Google Patents

同位素修饰的组分及其治疗用途 Download PDF

Info

Publication number
CN110167546A
CN110167546A CN201780078162.9A CN201780078162A CN110167546A CN 110167546 A CN110167546 A CN 110167546A CN 201780078162 A CN201780078162 A CN 201780078162A CN 110167546 A CN110167546 A CN 110167546A
Authority
CN
China
Prior art keywords
fatty acid
compound
polyunsaturated fatty
isotope
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780078162.9A
Other languages
English (en)
Chinese (zh)
Inventor
米哈伊尔·S·施柴匹诺维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Le Nest Tup Co Ltd
Original Assignee
Le Nest Tup Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Le Nest Tup Co Ltd filed Critical Le Nest Tup Co Ltd
Publication of CN110167546A publication Critical patent/CN110167546A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
    • A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90203—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Psychiatry (AREA)
CN201780078162.9A 2016-11-17 2017-11-16 同位素修饰的组分及其治疗用途 Pending CN110167546A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662423699P 2016-11-17 2016-11-17
US62/423,699 2016-11-17
PCT/US2017/062107 WO2018094116A1 (en) 2016-11-17 2017-11-16 Isotopically modified components and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
CN110167546A true CN110167546A (zh) 2019-08-23

Family

ID=62145748

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780078162.9A Pending CN110167546A (zh) 2016-11-17 2017-11-16 同位素修饰的组分及其治疗用途

Country Status (6)

Country Link
US (2) US11166930B2 (enExample)
JP (3) JP7132630B2 (enExample)
KR (1) KR102580606B1 (enExample)
CN (1) CN110167546A (enExample)
AU (2) AU2017363147B2 (enExample)
WO (1) WO2018094116A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116507325A (zh) * 2020-02-14 2023-07-28 拜奥吉瓦有限责任公司 用于治疗tau蛋白病的方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3536317A1 (en) * 2009-10-30 2019-09-11 Retrotope, Inc. Alleviating oxidative stress disorders with pufa derivatives
JP7132630B2 (ja) 2016-11-17 2022-09-07 レトロトップ、 インコーポレイテッド 同位体修飾成分及びその治療上の使用
AU2019255739A1 (en) * 2018-04-20 2020-11-12 Biojiva Llc Stabilized polyunsaturated compounds and uses thereof
CN109601803A (zh) * 2018-11-07 2019-04-12 江西颐迪科技有限公司 一种能消除老年人体味并有助健康的饮料及其制作方法
WO2020102596A1 (en) * 2018-11-15 2020-05-22 Retrotope, Inc. Deuterated compounds, compositions, and uses
CA3135402A1 (en) * 2019-04-04 2020-10-08 Dicerna Pharmaceuticals, Inc. Compositions and methods for inhibiting gene expression in the central nervous system
EP4103145A4 (en) * 2020-02-12 2024-07-03 Retrotope, Inc. DEUTERATED POLYUNSATURATED FATTY ACIDS OR THEIR ESTERS FOR COSMETIC APPLICATIONS
US11510889B2 (en) 2021-02-05 2022-11-29 Retrotope, Inc. Methods for inhibiting the progression of neurodegenerative diseases
US11351143B1 (en) * 2021-02-05 2022-06-07 Retrotope, Inc. Methods of treating amyotrophic lateral sclerosis
US11491130B2 (en) 2021-02-05 2022-11-08 Retrotope, Inc. Methods of treating amyotrophic lateral sclerosis
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS
WO2022170136A1 (en) * 2021-02-05 2022-08-11 Retrotope, Inc. Methods for assessing a patient's response to treatment of a neurodegenerative disease with deuterated arachidonic acid
EP4452244A4 (en) 2021-12-21 2026-02-18 Biojiva Llc ANTI-INFLAMMATORY METHODS INVOLVING SITE-SPECIFIC COMPOSITIONS COMPRISING ISOTOPICALLY MODIFIED FATTY ACIDS
WO2023158641A1 (en) * 2022-02-15 2023-08-24 Retrotope, Inc. Synergistic combination therapy for treating als
CN120435548A (zh) * 2022-12-01 2025-08-05 匹克生物酶高科技有限公司 用于解毒内源醛类的食品和药物组合物
KR20250110548A (ko) 2024-01-12 2025-07-21 현대모비스 주식회사 전기자동차용 배터리팩 케이스

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020081689A1 (en) * 2000-11-14 2002-06-27 Chunhua Yan Isolated human dehydrogenase proteins, nucleic acid molecules encoding these human dehydrogenase proteins, and uses thereof
US20030032078A1 (en) * 2001-01-23 2003-02-13 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of macular and retinal degenerations
US20110105609A1 (en) * 2009-10-30 2011-05-05 Retrotope, Inc. Alleviating oxidative stress disorders with pufa derivatives
US20120005765A1 (en) * 2010-07-01 2012-01-05 Saint Louis University Animal model for parkinson's disease
WO2012148930A2 (en) * 2011-04-26 2012-11-01 Retrotope, Inc. Oxidative retinal diseases
US20130309330A1 (en) * 2011-01-24 2013-11-21 Inceptum Research & Therapeutics, Inc. Compositions comprising a prostaglandin for treating neuropsychiatric conditions

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331532B1 (en) 1998-11-25 2001-12-18 University Of Otago Mitochondrially targeted antioxidants
US20030069208A1 (en) 1997-11-25 2003-04-10 University Of Otago Mitochondrially targeted antioxidants
US7635722B1 (en) * 1998-07-27 2009-12-22 Saint Jude Pharmaceuticals, Inc. Chemical induced intracellular hyperthermia
US20060229278A1 (en) 1998-11-25 2006-10-12 Antipodean Pharmaceuticals, Inc. Mitoquinone derivatives used as mitochondrially targeted antioxidants
US20080275005A1 (en) 1998-11-25 2008-11-06 Murphy Michael P Mitochondrially targeted antioxidants
US20070270381A1 (en) 2000-05-25 2007-11-22 Antipodean Pharmaceuticals, Inc. Mitochondrially targeted antioxidants
NZ513547A (en) 2001-08-13 2002-09-27 Antipodean Biotechnology Ltd Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone)
JP4648319B2 (ja) 2003-08-22 2011-03-09 アンティポディーン ファーマシューティカルズ インコーポレイティド ミトコンドリアを標的とする抗酸化剤として使用されるミトキノン誘導体
US7888334B2 (en) 2003-08-22 2011-02-15 Antipodean Pharmaceuticals, Inc. Mitoquinone derivatives used as mitochondrially targeted antioxidants
US20050065099A1 (en) 2003-09-19 2005-03-24 Gail Walkinshaw Treatment of mitochondrial diseases
PT1909600E (pt) * 2005-07-29 2012-07-24 Tima Foundation Composição para moderar o metabolismo do álcool e para reduzir o risco de doenças induzidas pelo álcool
JP2009508867A (ja) 2005-09-15 2009-03-05 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および関連した様態の治療ならびにエネルギーバイオマーカーの調節のための酸化還元活性治療剤のテイル改変体
JP5649454B2 (ja) 2008-01-08 2015-01-07 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病の処置のための（ヘテロ）アリール−ｐ−キノン誘導体
KR20160121610A (ko) 2008-04-01 2016-10-19 안티포딘 파마슈티칼스, 인코포레이티드 피부 관리를 위한 조성물 및 방법
WO2009137045A2 (en) * 2008-05-07 2009-11-12 The Board Of Trustees Of The Leland Stanford Junior University Crystal structure of aldehyde dehydrogenase and methods of use thereof
WO2010014758A1 (en) 2008-07-30 2010-02-04 Edison Pharmaceuticals, Inc. Use of hydrogenated pyrido[4,3-b] indoles for the treatment of oxidative stress
AU2012249920B2 (en) * 2011-04-26 2017-06-15 Biojiva Llc Disorders implicating PUFA oxidation
CA2834274C (en) * 2011-04-26 2021-08-03 Retrotope, Inc. Neurodegenerative disorders and muscle diseases implicating pufas
JP7132630B2 (ja) 2016-11-17 2022-09-07 レトロトップ、 インコーポレイテッド 同位体修飾成分及びその治療上の使用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020081689A1 (en) * 2000-11-14 2002-06-27 Chunhua Yan Isolated human dehydrogenase proteins, nucleic acid molecules encoding these human dehydrogenase proteins, and uses thereof
US20030032078A1 (en) * 2001-01-23 2003-02-13 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of macular and retinal degenerations
US20110105609A1 (en) * 2009-10-30 2011-05-05 Retrotope, Inc. Alleviating oxidative stress disorders with pufa derivatives
US20120005765A1 (en) * 2010-07-01 2012-01-05 Saint Louis University Animal model for parkinson's disease
US20130309330A1 (en) * 2011-01-24 2013-11-21 Inceptum Research & Therapeutics, Inc. Compositions comprising a prostaglandin for treating neuropsychiatric conditions
WO2012148930A2 (en) * 2011-04-26 2012-11-01 Retrotope, Inc. Oxidative retinal diseases
US20140044693A1 (en) * 2011-04-26 2014-02-13 Retrotope, Inc. Oxidative retinal diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MIKHAIL S. SHCHEPINOV: "Isotopic reinforcement of essential polyunsaturated fatty acids diminishes", 《TOXICOLOGY LETTERS》 *
MIKHAIL S.SHCHEPINOV ET AL.,: "Chapter 31 - Deuterium Protection of Polyunsaturated Fatty Acids against Lipid Peroxidation: A Novel Approach to Mitigating Mitochondrial Neurological Diseases", 《OMEGA-3 FATTY ACIDS IN BRAIN AND NEUROLOGICAL HEALTH》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116507325A (zh) * 2020-02-14 2023-07-28 拜奥吉瓦有限责任公司 用于治疗tau蛋白病的方法

Also Published As

Publication number Publication date
KR20190085973A (ko) 2019-07-19
JP2020500193A (ja) 2020-01-09
US20190282529A1 (en) 2019-09-19
AU2017363147B2 (en) 2023-09-14
US20220133668A1 (en) 2022-05-05
JP7132630B2 (ja) 2022-09-07
AU2023282263A1 (en) 2024-01-18
KR102580606B1 (ko) 2023-09-19
JP7464661B2 (ja) 2024-04-09
AU2017363147A1 (en) 2019-05-23
JP2024081733A (ja) 2024-06-18
US11166930B2 (en) 2021-11-09
WO2018094116A1 (en) 2018-05-24
JP2022166245A (ja) 2022-11-01

Similar Documents

Publication Publication Date Title
JP7464661B2 (ja) 同位体修飾成分及びその治療上の使用
JP6506206B2 (ja) Ｐｕｆａ誘導体による酸化ストレス障害の緩和
JP6374551B2 (ja) 酸化的網膜疾患
ES2449150T3 (es) Compuestos y métodos para tratar la degeneración muscular
ES2585066T3 (es) Composiciones para el tratamiento de trastornos neurológicos
AU2019204443B2 (en) Optic neuropathy treatment and reduction of steroid-induced oxidative stress with stabilized polyunsaturated substances
US9254280B2 (en) Medical food for cognitive decline
EA015566B1 (ru) Применение пептидного соединения для добавочной терапии к антагонисту дофамина и фармацевтическая композиция, его содержащая
CN114007607A (zh) 用于治疗神经变性疾病的材料和方法
Liu et al. Role of long-chain and very-long-chain polyunsaturated fatty acids in macular degenerations and dystrophies
HK40011999A (en) Isotopically modified components and therapeutic uses thereof
JP2008019242A (ja) 神経細胞保護剤
EP3335730A1 (en) Compounds for treating x-linked adrenoleukodystrophy
JP7570108B2 (ja) ミトコンドリア病の治療における使用のためのカンナビジオールおよび／またはその誘導体
CN119730845A (zh) 用于改善视网膜/认知功能和动脉粥样硬化的极长链多不饱和脂肪酸（vlcpufa）

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40011999

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190823